Literature DB >> 24399853

Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer.

Ayal A Aizer1, Jonathan J Paly, M Dror Michaelson, Sandhya K Rao, Paul L Nguyen, Irving D Kaplan, Andrzej Niemierko, Aria F Olumi, Jason A Efstathiou.   

Abstract

PURPOSE: Specialist bias, in which specialists recommend the therapy that they are capable of delivering, is thought to influence the treatment of patients with localized prostate cancer and to contribute to overtreatment of men with limited life expectancy. Consequently, rates of active surveillance, the preferred management modality per the National Comprehensive Cancer Network (NCCN) for patients with low- and very low-risk disease and a life expectancy of less than 10 and less than 20 years, respectively, are low. We sought to determine whether consultation with a medical oncologist is associated with increased rates of active surveillance in men with low-risk prostate cancer.
METHODS: We identified 188 patients with low-risk prostate cancer undergoing active surveillance at one of three referral centers in Boston, MA in 2009. Multivariable logistic regression was used to determine whether consultation with a medical oncologist was associated with selection of active surveillance. The data were reanalyzed for patients with low- and very low-risk disease and a life expectancy of less than 10 and less than 20 years, respectively.
RESULTS: Consultation with a medical oncologist was associated with increased rates of active surveillance (37% v 21%, P = .01), an association that remained significant on multivariable logistic regression (odds ratio [OR] = 2.70; 95% CI, 1.27 to 5.75; P = .01). When applied to patients with limited life expectancy, this finding remained significant (OR = 4.74; 95% CI, 1.17 to 19.25; P = .03).
CONCLUSION: Consultation with a medical oncologist is associated with increased rates of active surveillance, adherence to NCCN guidelines, and minimization of overtreatment in men with early prostate cancer and limited life expectancy.

Entities:  

Mesh:

Year:  2014        PMID: 24399853     DOI: 10.1200/JOP.2013.000902

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  4 in total

1.  Multidisciplinary Oncology Education: Going Beyond Tumor Board.

Authors:  Malcolm D Mattes
Journal:  J Am Coll Radiol       Date:  2016-07-27       Impact factor: 5.532

Review 2.  Achieving optimal delivery of follow-up care for prostate cancer survivors: improving patient outcomes.

Authors:  Shawna V Hudson; Denalee M O'Malley; Suzanne M Miller
Journal:  Patient Relat Outcome Meas       Date:  2015-03-19

Review 3.  An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer.

Authors:  Axel S Merseburger; Marie C Hupe
Journal:  Adv Ther       Date:  2016-05-31       Impact factor: 3.845

4.  Describing perspectives of health care professionals on active surveillance for the management of prostate cancer.

Authors:  Kittie Pang; Margaret Fitch; Veronique Ouellet; Simone Chevalier; Darrel E Drachenberg; Antonio Finelli; Jean-Baptiste Lattouf; Alan So; Simon Sutcliffe; Simon Tanguay; Fred Saad; Anne-Marie Mes-Masson
Journal:  BMC Health Serv Res       Date:  2018-06-08       Impact factor: 2.655

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.